The optimal use of bexarotene in cutaneous T-cell lymphoma
2007/06/06 by R. Gniadecki, Robert Gniadecki, C. Assaf +14 · 26 citations
Medicine · Immunology and Microbiology · #Cutaneous lymphoproliferative disorders research #T-cell and Retrovirus Studies #Nail Diseases and Treatments
paper · doi:10.1111/j.1365-2133.2007.07975.x
Abstract
The management goal in cutaneous T-cell lymphomas (CTCLs) is to improve symptoms and induce remission. Early-stage disease is generally treated with skin-directed therapies. However, if these do not control the disease, systemic therapy becomes necessary. Bexarotene, a novel rexinoid, is an oral, noncytotoxic drug that has been approved in Europe for the treatment of refractory advanced-stage CTCL and in the U.S.A. for refractory CTCL. We provide guidance on the use of bexarotene in the management of CTCL, based on data from phase II/III clinical trials and the authors' clinical experience, and suggest how the potential of the drug can be maximized. The clinical trial results with bexarotene are reviewed, especially in comparison with interferon-alpha, which is the other commonly used noncytotoxic systemic therapy for CTCL. A treatment algorithm for bexarotene in refractory CTCL is suggested. As bexarotene may take time to achieve a maximum response, this algorithm recommends that therapy should be continued for a sufficient period to allow for a delayed onset of action. In addition, possible combination therapies with bexarotene are discussed. We conclude that bexarotene is effective in the management of CTCL, and has the advantage of oral administration. An on-going randomized clinical trial comparing psoralen plus ultraviolet A (PUVA) with PUVA plus bexarotene will provide valuable information about this combination regimen in early-stage disease, but further data are needed on the relative efficacies of other combination therapies with bexarotene in CTCL.
Citations
Cited by
- U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma
- Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents. [europepmc]
- Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential. [europepmc]
- Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. [europepmc]
- Identification of Bexarotene as a PPARγ Antagonist with HDX. [europepmc]
- Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. [europepmc]
- Effect of a retinoid X receptor partial agonist on airway inflammation and hyperresponsiveness in a murine model of asthma. [europepmc]
- Suppressive effects of RXR agonist PA024 on adrenal CYP11B2 expression, aldosterone secretion and blood pressure. [europepmc]
- Bexarotene Enhances Macrophage Erythrophagocytosis and Hematoma Clearance in Experimental Intracerebral Hemorrhage. [europepmc]
- Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. [europepmc]
- Reaction Pathways and Redox States in α-Selective Cobalt-Catalyzed Hydroborations of Alkynes. [europepmc]
- Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature. [europepmc]
- Stability of the Retinoid X Receptor-α Homodimer in the Presence and Absence of Rexinoid and Coactivator Peptide. [europepmc]
- Iridium-catalyzed C-H methylation and d 3 -methylation of benzoic acids with application to late-stage functionalizations. [europepmc]
- Pharmacological Activation of RXR-α Promotes Hematoma Absorption via a PPAR-γ-dependent Pathway After Intracerebral Hemorrhage. [europepmc]
- Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo-PrP C binding and downstream pathways. [europepmc]
- Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. [europepmc]
- Cytoplasmic Localization of RXRα Determines Outcome in Breast Cancer. [europepmc]
- Targeting BRF2 in Cancer Using Repurposed Drugs. [europepmc]
- In silico Repurposing of Drugs for pan-HDAC and pan-SIRT Inhibitors: Consensus Structure-based Virtual Screening and Pharmacophore Modeling Investigations. [europepmc]
- Structural overview and perspectives of the nuclear receptors, a major family as the direct targets for small-molecule drugs. [europepmc]
- Bexarotene-induced cell death in ovarian cancer cells through Caspase-4-gasdermin E mediated pyroptosis. [europepmc]
- Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. [europepmc]
- Regulation of HDAC11 gene expression in early myogenic differentiation. [europepmc]
- Attempts to Improve Lipophilic Drugs' Solubility and Bioavailability: A Focus on Fenretinide. [europepmc]
- The role of silicon in drug discovery: a review. [europepmc]
Related